Press Release Oct 06 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Brivaracetam Tablets, along with shared exclusivity rights. The approval allows Zydus to market multiple strengths of Brivaracetam Tablets, which are used to treat partial-onset seizures in patients aged four and older. This filing highlights Zydus's position as one of the first applicants to submit a complete application for this drug, qualifying for a period of exclusivity. The drug will be manufactured at Zydus's facility in Ahmedabad, India, and had significant annual sales in the US market according to recent data.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 04 2022
- Press Release Oct 03 2022
- Press Release Oct 01 2022
- Press Release Sep 20 2022
- Press Release Sep 16 2022
Later from Zydus Lifesciences
- Zydus Lifesciences: General updates
- Press Release Oct 17 2022
- Press Release Oct 22 2022
- Press Release Oct 26 2022
- Press Release Oct 29 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences